Specialty pharma firm Advicenne has signed a supply agreement with the pharmaceutical contract development and manufacturing organization (CDMO) Elaiapharm Lundbeck for the manufacturing of its lead product, with a view to its worldwide commercialization as a treatment for distal Renal Tubular Acidosis (dRTA).   Based in Sophia Antipolis, France, Elaiapharm is a wholly owned subsidiary of H. Lundbeck A/S. Under the agreement, Elaiapharm will secure manufacturing for the global commercialization ...